Aldeyra Therapeutics to Host Investor Roundtable QA
Aldeyra Therapeutics to Host Investor Roundtable QA
Event Scheduled for Thursday, June 20 at 8:00 a.m. ET
活动定于2019年6月20日 上午8:00美国东部时间
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 12, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET.
美国马萨诸塞州列克星敦市--（美国商业资讯)--2024年6月12日--Aldeyra Therapeutics, Inc.（纳斯达克: ALDX）（Aldeyra）是一家专注于开发创新疗法，致力于治疗免疫介导和代谢性疾病的生物技术公司，今天宣布该公司将于2024年6月20日星期四东部时间上午8:00通过网络直播举办投资者圆桌问答活动。
The call will include prepared remarks from Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, followed by a Q&A session. The call will be open to all current and prospective Aldeyra shareholders, and participants will be able to submit questions through the webcast portal during the event. In addition, beginning Monday, June 17, investors will be able to submit questions ahead of the call via email to investorrelations@aldeyra.com.
该会议将包括来自Todd C. Brady, M.D.博士，Ph.D.总裁兼首席执行官的发言，之后是问答环节。这次电话会议将对所有现有和潜在的Aldeyra股东开放，参与者将能够在活动期间通过网络直播门户提交问题。此外，从6月17日星期一开始，投资者们将能够通过电子邮件事先提交问题。investorrelations@aldeyra.com.
A live audio webcast and slide presentation will be accessible from the "Investors & Media" section of the Aldeyra website at https://ir.aldeyra.com/. A replay will be available for 90 days following the event.
现场音频网上直播和幻灯片演示将从Aldeyra网站的“投资者和媒体”(Investors & Media)部分处获得。网站链接为：https://ir.aldeyra.com/。活动后90天内，将提供重播。关于Aldeyra回放将在活动结束后90天内提供。
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
关于Aldeyra
Aldeyra Therapeutics是一家专注于发现旨在治疗免疫介导和代谢性疾病的创新疗法的生物技术公司。我们的方法是开发调节蛋白质系统的药品，而不是直接抑制或激活单个蛋白靶标，以期在最小化毒性的同时优化多条途径。我们的产品候选包括RASP（活性醛类物质）调节剂ADX-629、ADX-246、ADX-248和与之化学相关的分子，用于潜在治疗免疫介导和代谢性疾病。我们的后期产品候选包括reproxalap，一种RASP调节剂，可潜在治疗干眼病和过敏性结膜炎，以及ADX-2191，一种新型眼内注射甲氨蝶呤制剂，可潜在治疗视网膜色素变性症。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612329514/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240612329514/en/
Investor & Media:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
投资者和媒体：
David Burke
电话：(917) 618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
来源：Aldeyra Therapeutics股份有限公司